{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:26:35Z","timestamp":1783970795341,"version":"3.55.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":3150,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s13311-014-0318-6","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T07:12:15Z","timestamp":1416553935000},"page":"250-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats"],"prefix":"10.1016","volume":"12","author":[{"given":"Rita","family":"Citraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-014-0318-6_bib1","first-page":"37","article-title":"Antipsychotic medications and seizures","volume":"9","author":"Marks","year":"1991","journal-title":"Psychiatr Med"},{"key":"10.1007\/s13311-014-0318-6_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2174\/138920011796504473","article-title":"Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems","volume":"12","author":"Trifiro","year":"2011","journal-title":"Curr Drug Metab"},{"issue":"Suppl. 8","key":"10.1007\/s13311-014-0318-6_bib3","first-page":"5","article-title":"An overview of side effects caused by typical antipsychotics","volume":"61","author":"Arana","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00044011-200323050-00001","article-title":"Conventional and atypical antipsychotics in the elderly: A review","volume":"23","author":"Gareri","year":"2003","journal-title":"Clin Drug Investig"},{"key":"10.1007\/s13311-014-0318-6_bib5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/00002512-200623120-00002","article-title":"Adverse effects of atypical antipsychotics in the elderly: A review","volume":"23","author":"Gareri","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1007\/s13311-014-0318-6_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.7.5.525","article-title":"The safety of clozapine in the elderly","volume":"7","author":"Gareri","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1007\/s13311-014-0318-6_bib7","first-page":"S68","article-title":"Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations","volume":"53","author":"Alldredge","year":"1999","journal-title":"Neurology"},{"key":"10.1007\/s13311-014-0318-6_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2012.10.009","article-title":"Antipsychotics and seizures: higher risk with atypicals?","volume":"22","author":"Lertxundi","year":"2013","journal-title":"Seizure"},{"key":"10.1007\/s13311-014-0318-6_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1358\/dot.2003.39.7.799445","article-title":"Antipsychotic medication and seizures: a review","volume":"39","author":"Hedges","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"10.1007\/s13311-014-0318-6_bib10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1474-4422(12)70201-6","article-title":"Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?","volume":"11","author":"Kanner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-014-0318-6_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.yebeh.2012.01.007","article-title":"Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence","volume":"24","author":"Kanner","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-014-0318-6_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5698\/1535-7511-11.2.50","article-title":"Is depression a risk factor of worse response to therapy in epilepsy?","volume":"11","author":"Kanner","year":"2011","journal-title":"Epilepsy Curr"},{"issue":"Suppl. 1","key":"10.1007\/s13311-014-0318-6_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1528-1167.2010.02907.x","article-title":"Depression and epilepsy: A bidirectional relation?","volume":"52","author":"Kanner","year":"2011","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-014-0318-6_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ana.20685","article-title":"Depression and suicide attempt as risk factors for incident unprovoked seizures","volume":"59","author":"Hesdorffer","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-014-0318-6_bib15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S0140-6736(55)90642-5","article-title":"Complications of chlorpromazine therapy in 800 mental-hospital patients","volume":"268","author":"Lomas","year":"1955","journal-title":"Lancet"},{"issue":"Suppl. 10","key":"10.1007\/s13311-014-0318-6_bib16","first-page":"55","article-title":"The relationship of pharmacology to side effects","volume":"58","author":"Casey","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.seizure.2009.11.005","article-title":"Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database","volume":"19","author":"Kumlien","year":"2010","journal-title":"Seizure"},{"key":"10.1007\/s13311-014-0318-6_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","article-title":"Effects of psychotropic drugs on seizure threshold","volume":"25","author":"Pisani","year":"2002","journal-title":"Drug Saf"},{"key":"10.1007\/s13311-014-0318-6_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0920-1211(96)00061-7","article-title":"Kindling with clozapine: behavioral and molecular consequences","volume":"26","author":"Stevens","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-014-0318-6_bib20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.pnpbp.2010.12.009","article-title":"Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats","volume":"35","author":"Celikyurt","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/alcalc\/agn052","article-title":"Effects of clozapine on ethanol withdrawal syndrome in rats","volume":"43","author":"Kayir","year":"2008","journal-title":"Alcohol Alcohol"},{"key":"10.1007\/s13311-014-0318-6_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejphar.2007.10.024","article-title":"Effects of olanzapine on ethanol withdrawal syndrome in rats","volume":"579","author":"Unsalan","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.neuropharm.2012.06.039","article-title":"Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity","volume":"64","author":"Russo","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib24","first-page":"311","article-title":"Neuronal networks in the genetically epilepsy-prone rat","volume":"79","author":"Faingold","year":"1999","journal-title":"Adv Neurol"},{"key":"10.1007\/s13311-014-0318-6_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0006-8993(96)00616-6","article-title":"Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CGP [corrected] 37849 and CGP 39551 in genetically epilepsy-prone rats","volume":"734","author":"De Sarro","year":"1996","journal-title":"Brain Res"},{"key":"10.1007\/s13311-014-0318-6_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/PL00005027","article-title":"Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats","volume":"356","author":"De Sarro","year":"1997","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0920-1211(89)90063-6","article-title":"Neurobiology of seizure predisposition in the genetically epilepsy-prone rat","volume":"3","author":"Dailey","year":"1989","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-014-0318-6_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0920-1211(89)90023-5","article-title":"Audiogenic convulsions in moderate seizure genetically epilepsy-prone rats (GEPR-3s)","volume":"3","author":"Mishra","year":"1989","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-014-0318-6_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0920-1211(89)90059-4","article-title":"Ontogeny of sound-induced seizures in the genetically epilepsy-prone rat","volume":"4","author":"Reigel","year":"1989","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-014-0318-6_bib30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0024-3205(86)90454-6","article-title":"The genetically epilepsy-prone rat: an overview of seizure-prone characteristics and responsiveness to anticonvulsant drugs","volume":"39","author":"Reigel","year":"1986","journal-title":"Life Sci"},{"key":"10.1007\/s13311-014-0318-6_bib31","first-page":"2640","article-title":"Anticonvulsant drugs and the genetically epilepsy-prone rat","volume":"44","author":"Dailey","year":"1985","journal-title":"Fed Proc"},{"key":"10.1007\/s13311-014-0318-6_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0028-3908(93)90129-Q","article-title":"Anticonvulsant properties of non-competitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene","volume":"32","author":"De Sarro","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0028-3908(91)90200-U","article-title":"Responsiveness of genetically epilepsy-prone rats to aminophylline-induced seizures and interactions with quinolones","volume":"30","author":"De Sarro","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)29378-8","article-title":"Role of brain norepinephrine in audiogenic seizure in the rat","volume":"184","author":"Jobe","year":"1973","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-014-0318-6_bib35","first-page":"183","article-title":"Scope and contribution of genetic models to an understanding of the epilepsies","volume":"6","author":"Jobe","year":"1991","journal-title":"Crit Rev Neurobiol"},{"key":"10.1007\/s13311-014-0318-6_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2011.02.013","article-title":"Preclinical activity profile of alpha-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy","volume":"95","author":"Citraro","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-014-0318-6_bib37","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0024-3205(88)90607-8","article-title":"Brain norepinephrine and convulsions in the genetically epilepsy-prone rat: Sex-dependent responses to Ro 4-1284 treatment","volume":"42","author":"Mishra","year":"1988","journal-title":"Life Sci"},{"key":"10.1007\/s13311-014-0318-6_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0024-3205(86)90455-8","article-title":"Noradrenergic and serotonergic determinants of seizure susceptibility and severity in genetically epilepsy-prone rats","volume":"39","author":"Jobe","year":"1986","journal-title":"Life Sci"},{"key":"10.1007\/s13311-014-0318-6_bib39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.neuropharm.2004.08.021","article-title":"Anticonvulsant effects of carbenoxolone in genetically epilepsy prone rats (GEPRs)","volume":"47","author":"Gareri","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1528-1167.2011.03112.x","article-title":"Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model","volume":"52","author":"Russo","year":"2011","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-014-0318-6_bib41","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/(SICI)1098-2396(199807)29:3<272::AID-SYN10>3.0.CO;2-V","article-title":"Acute and chronic administration of clozapine produces greater proconvulsant actions than haloperidol on focal hippocampal seizures in freely moving rats","volume":"29","author":"Minabe","year":"1998","journal-title":"Synapse"},{"key":"10.1007\/s13311-014-0318-6_bib42","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1124\/jpet.103.052597","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment","volume":"306","author":"Tarazi","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-014-0318-6_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pnpbp.2005.08.020","article-title":"Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats","volume":"30","author":"Ortega-Alvaro","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib44","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/j.1528-1167.2009.02400.x","article-title":"Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy","volume":"51","author":"Russo","year":"2010","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-014-0318-6_bib45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbr.2011.07.030","article-title":"Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity","volume":"225","author":"Russo","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1007\/s13311-014-0318-6_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuropharm.2012.09.019","article-title":"mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy","volume":"69","author":"Russo","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib47","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/epi.12686","article-title":"Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG\/Rij rats, a genetic animal model of absence epilepsy","volume":"55","author":"Citraro","year":"2014","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-014-0318-6_bib48","first-page":"223","article-title":"Neurobiology of seizure predisposition in the genetically epilepsy prone rat","volume":"34","author":"Jobe","year":"1991","journal-title":"Proc West Pharmacol Soc"},{"key":"10.1007\/s13311-014-0318-6_bib49","doi-asserted-by":"crossref","unstructured":"Russo E, Donato di Paola E, Gareri P, et al. Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA\/2 mice. Pharmacol Res 2013;70:1\u201312.","DOI":"10.1016\/j.phrs.2012.12.002"},{"key":"10.1007\/s13311-014-0318-6_bib50","first-page":"49","article-title":"Anticonvulsant activity of some calcium antagonists in genetically epilepsy prone rats","volume":"3","author":"De Sarro","year":"1991","journal-title":"Epilepsy Res Suppl"},{"key":"10.1007\/s13311-014-0318-6_bib51","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ijdevneu.2008.07.002","article-title":"Effects of ethanol on the development of genetically determined epilepsies in rats","volume":"26","author":"Russo","year":"2008","journal-title":"Int J Dev Neurosci"},{"key":"10.1007\/s13311-014-0318-6_bib52","doi-asserted-by":"crossref","unstructured":"Gareri P, Cotroneo A, Lacava R, et al. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl 2004:207\u2013215.","DOI":"10.1016\/j.archger.2004.04.029"},{"key":"10.1007\/s13311-014-0318-6_bib53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-002-1016-3","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions","volume":"161","author":"Tarazi","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-014-0318-6_bib54","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17385","article-title":"Seizure associated with olanzapine","volume":"33","author":"Lee","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1007\/s13311-014-0318-6_bib55","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0306-4522(96)00631-8","article-title":"Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment","volume":"78","author":"Tarazi","year":"1997","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-014-0318-6_bib56","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.neuropharm.2011.08.031","article-title":"Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission","volume":"62","author":"Tanahashi","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0031-6997(24)01483-2","article-title":"Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects","volume":"53","author":"Strange","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1007\/s13311-014-0318-6_bib58","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib59","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/14656566.8.9.1211","article-title":"A preclinical and clinical rationale for quetiapine in mood syndromes","volume":"8","author":"McIntyre","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1007\/s13311-014-0318-6_bib60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0b013e31827b97a6","article-title":"Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia","volume":"33","author":"Lerond","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib62","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/14656566.1.7.1441","article-title":"Pharmacology and clinical experience with risperidone","volume":"1","author":"Love","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1007\/s13311-014-0318-6_bib63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1124\/jpet.111.183780","article-title":"Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo","volume":"339","author":"Yadav","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-014-0318-6_bib64","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib65","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00213-010-2001-x","article-title":"Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions","volume":"212","author":"Teitler","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-014-0318-6_bib66","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","article-title":"Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality","volume":"27","author":"Svensson","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib67","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00213-014-3459-8","article-title":"alpha2-Adrenoceptors are targets for antipsychotic drugs","volume":"231","author":"Brosda","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-014-0318-6_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01308-6","article-title":"alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs","volume":"462","author":"Kalkman","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib69","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality","volume":"27","author":"Bymaster","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib70","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","article-title":"The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain","volume":"27","author":"He","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-014-0318-6_bib71","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/sj.bjp.0704608","article-title":"The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics","volume":"135","author":"Yokota","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib72","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0006-8993(97)01139-6","article-title":"Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study","volume":"780","author":"Yan","year":"1998","journal-title":"Brain Res"},{"key":"10.1007\/s13311-014-0318-6_bib73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0897-387","article-title":"Sound-induced seizures in serotonin 5-HT2c receptor mutant mice","volume":"16","author":"Brennan","year":"1997","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-014-0318-6_bib74","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/exnr.1998.6901","article-title":"Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: a behavioral analysis","volume":"154","author":"Applegate","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-014-0318-6_bib75","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","article-title":"Dopamine and serotonin receptor binding and antipsychotic efficacy","volume":"32","author":"Richtand","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib76","first-page":"175","article-title":"New pharmacological approaches to the treatment of schizophrenia","volume":"20","author":"Uzbay","year":"2009","journal-title":"Turk Psikiyatri Derg"},{"key":"10.1007\/s13311-014-0318-6_bib77","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/npp.1993.50","article-title":"Tissue concentrations of clozapine and its metabolites in the rat","volume":"9","author":"Baldessarini","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib78","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hup.375","article-title":"Epilepsy, psychosis and clozapine","volume":"17","author":"Langosch","year":"2002","journal-title":"Hum Psychopharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib79","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/1086508X.2007.11079630","article-title":"Clozapine (Clozaril), seizures, and EEG abnormalities","volume":"47","author":"White","year":"2007","journal-title":"Am J Electroneurodiagnostic Technol"},{"key":"10.1007\/s13311-014-0318-6_bib80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/alcalc\/agr142","article-title":"Atypical antipsychotic drugs and ethanol withdrawal syndrome: a review","volume":"47","author":"Uzbay","year":"2012","journal-title":"Alcohol Alcohol"},{"key":"10.1007\/s13311-014-0318-6_bib81","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0376-8716(89)90066-5","article-title":"On the relative importance of D-1 vs. D-2 dopaminergic receptors in the control of audiogenic seizures in ethanol withdrawn rats","volume":"24","author":"Trzaskowska","year":"1989","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-014-0318-6_bib82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0376-8716(98)00102-1","article-title":"Dopaminergic and serotonergic alterations in the rat brain during ethanol withdrawal: association with behavioral signs","volume":"53","author":"Uzbay","year":"1998","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-014-0318-6_bib83","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0278-5846(00)00133-0","article-title":"Monoaminergic changes associated with audiogenic seizures in ethanol-dependent rats","volume":"24","author":"Yu","year":"2000","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib84","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00241089","article-title":"Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats","volume":"350","author":"Yan","year":"1994","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib85","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/sj.bjp.0701975","article-title":"The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat","volume":"124","author":"Kalkman","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1007\/s13311-014-0318-6_bib86","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0006-8993(93)91212-B","article-title":"Noradrenergic mechanisms for the anticonvulsant effects of desipramine and yohimbine in genetically epilepsy-prone rats: studies with microdialysis","volume":"610","author":"Yan","year":"1993","journal-title":"Brain Res"},{"key":"10.1007\/s13311-014-0318-6_bib87","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0735-6757(98)90001-8","article-title":"Effects of risperidone in overdose","volume":"16","author":"Acri","year":"1998","journal-title":"Am J Emerg Med"},{"key":"10.1007\/s13311-014-0318-6_bib88","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00421114","article-title":"Studies on the effects of histaminergic agents on seizure susceptibility in mice","volume":"46","author":"Gerald","year":"1976","journal-title":"Psychopharmacologia"},{"issue":"(Suppl.) 2","key":"10.1007\/s13311-014-0318-6_bib89","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1007\/PL00022416","article-title":"Histamine H1-antagonists potentiate seizures in the EL (epilepsy-like) mouse model of temporal lobe epilepsy","volume":"50","author":"Sturman","year":"2001","journal-title":"Inflamm Res"},{"key":"10.1007\/s13311-014-0318-6_bib90","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-014-0318-6_bib91","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4088\/JCP.v67n0619b","article-title":"Aripiprazole-associated seizure","volume":"67","author":"Tsai","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib92","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pnpbp.2009.08.025","article-title":"Serious generalized tonic-clonic seizures induced by aripiprazole","volume":"34","author":"Lin","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib93","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1007\/s13311-014-0318-6_bib94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1192\/bjp.178.1.85-a","article-title":"Lowered seizure threshold on olanzapine","volume":"178","author":"Woolley","year":"2001","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-014-0318-6_bib95","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.wnf.0000165351.10841.fa","article-title":"Olanzapine-induced myoclonic status","volume":"28","author":"Camacho","year":"2005","journal-title":"Clin Neuropharmacol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-014-0318-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-014-0318-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-014-0318-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:43:25Z","timestamp":1761806605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923008681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1878747923008681"],"URL":"https:\/\/doi.org\/10.1007\/s13311-014-0318-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-014-0318-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}